The article presents a study concerning binase and other microbial RNases as potential anticancer agents. It focuses on the authors' proposal of an alternative platform for anticancer therapy based on T1 RNases of microbial origin, Bacillus intermedius and Streptomyces aureofaciens in particular. Their advantages and potential clinical applications are also discussed.